Marotta Asset Management Sells 1,533 Shares of Johnson & Johnson $JNJ

Key Points

• Marotta Asset Management has reduced its holdings in Johnson & Johnson by 53.7%, now owning 1,321 shares valued at approximately $202,000.
• Analysts have given Johnson & Johnson a current average rating of “Moderate Buy” with an average price target of $176.29.
• Johnson & Johnson recently reported earnings of $2.77 EPS for the quarter, exceeding expectations, with a quarterly revenue of $23.74 billion.

Marotta Asset Management decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 53.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,321 shares of the company's stock after selling 1,533 shares during the quarter. Marotta Asset Management's holdings in Johnson & Johnson were worth $202,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Highline Wealth Partners LLC increased its holdings in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the first quarter worth $52,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on JNJ shares. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Bank of America upped their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Guggenheim reiterated a "neutral" rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Wall Street Zen upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Barclays upped their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Stock Down 0.2%

Shares of NYSE:JNJ opened at $178.10 on Friday. The company has a market capitalization of $428.93 billion, a PE ratio of 19.05, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The business has a fifty day moving average price of $170.81 and a two-hundred day moving average price of $161.30. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is 55.61%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.